Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 02, 2024 2:40pm
RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events
June 2024 - AstraZeneca and Daiichi Sankyo are now developing datopotamab deruxtecan (Dato-DXd). In October 2023, results presented at the European Society for Medical Oncology Congress
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 02, 2024 2:19pm
RE:RE:RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill
As lawyers at Sullivan IP Solutions see it, Pfizer shouldn’t have gone to the federal court, because “an arbitrator’s award is rarely overturned,” especially as the arbitrator was a retired federal
...more
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource
posted Sep 19, 2024 9:00am by
Northstar Gold Corp.
-
|
The MOU grants Hunan Nonferrous the opportunity to explore and develop a near-surface NI43-101 gold mineral resource at Northstar’s 100%-owned Miller Copper-Gold Property, located 18 kilometers southeast of Kirkland Lake, Ontario. This will be achieved by diamond drilling up to 10,000 meters, allowing Hunan Nonferrous to earn a negotiated interest in the resultant NI43-101 gold resource. ...read more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 02, 2024 2:05pm
RE:RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill
The board's decision in Seagen is not surprising. Rather, it is consistent with the U.S. Patent and Trademark Office's guidelines for assessing enablement in utility applications and patents
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 02, 2024 1:47pm
RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill
For Pfizer and it's US$43 Billion acquisition of Seagen and the subsequent invalidation of Seagen's U.S. Patent No. 10,808,039, which is the cornerstone of the trastuzumab-deruxtecan
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 02, 2024 1:17pm
RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill
February 23, 2024, - The latest chapter in the complex and multifaceted Daiichi Sankyo Inc. v. Seagen Inc.[Pfizer] patent dispute — concerning antibody-drug conjugate technology, or ADC, and
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Sep 02, 2024 12:59pm
Sanofi Phase 3 drug stumbles but still filing for approval
September 02, 2024 - Sanofi is still set on taking its multiple sclerosis (MS) med tolebrutinib to the FDA, executives have told Fierce Biotech, despite the BTK inhibitor falling short in two of three
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 02, 2024 12:23pm
RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill
August 28, 2024 - The USPTO’s May 2024 proposed anti-patent thicket rule, which promotes competition by lowering the cost of challenging groups of patents linked by terminal disclaimers, is also
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 02, 2024 9:50am
RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024
In 2021 the US imposed changes to the way it allows companies to deduct R&D expenses such that now most companies must amortize those costs over 5 years. Starting in 2022, companies can
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 01, 2024 7:26pm
RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024
In April 2024 Deloitte reported on how the current R&D operating model within pharma continues to experience significant pressures. This is due to ongoing regulatory changes, the impending and
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 01, 2024 4:18pm
RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024
Big Pharma has been listening and has restructured their in-house R&D corporate organizations in advance of impending accelerated deal-making and M&A initiatives. August 08, 2024 - WSJ - Big
...more
(5618)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Sep 01, 2024 3:54pm
RE:RE:ONCY Initiates New Pancreatic Cancer GOBLET Cohort
August 30, 2024 - Tumor microenvironment: recent advances in immunotherapies of pancreatic cancer This yet-to-be published review focuses on the significance importance of the tumor microenvironment
...more
(1395)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Sep 01, 2024 1:59pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
Good point. It's almost as if the big players don't go on to chat rooms to hear what's going on with the company. It's a new-ish approach to oncology. We're front row when
...more
(179)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Sep 01, 2024 1:13pm
RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
The price action speaks volumes. Nobody cares about the positives being spun on this chat.
(183)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Sep 01, 2024 11:56am
RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
There's something out there mucking up the water. That's the point. With all these positives, what/who in the world is holding this stock back? Every stock has spurts. Here, it's as if
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
EnviroGold Global Announces Appointment of Chief Operating Officer
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed